drugset / Trial / NCT03139253
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.
Timeline
- Start
- 2017-05-30
- Primary completion
- 2017-06-30
- Completion
- 2017-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | 1000 mg | — |
| Subject | Clarithromycin | Small molecule | 500 mg | — |
| Subject | Furazolidone | Small molecule | 100 mg | — |
| Subject | Ilaprazole | Small molecule | 5 mg | — |
| Subject | Levofloxacin | Small molecule | 500 mg | — |
| Subject | Tetracycline | Unknown | 750 mg | — |
| Subject | tinidazole | Small molecule | 500 mg | — |
Indications
No indication recorded.